Secukinumab for treating moderate to severe hidradenitis suppurativa

Secukinumab (Cosentyx, Novartis) is indicated for the treatment of 'active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy'.

The dosage schedule is available in the summary of product characteristics for secukinumab.

The list price of secukinumab is £1,218.78 per 300 mg/2 ml solution for injection pre-filled pen, or per 2 x 150 mg/1 ml solution for injection pre-filled pens (excluding VAT; BNF online accessed April 2023). The company has a commercial arrangement. This makes secukinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.